Top Industry Leaders in the Chikungunya Vaccine Market
Latest Chikungunya Vaccine Companies Updates:
Valneva: Their chikungunya vaccine, VLA1553 (Ixchiq®), received FDA approval in November 2023 and EMA approval in December 2023, marking a major milestone for the market.
Valneva is actively launching the vaccine in the US and targeting further approvals in other countries.
Bavarian Nordic: Their chikungunya vaccine candidate, PXVX0317, is undergoing Phase 3 clinical trials and is expected to seek regulatory approval in 2024. This could provide another option for the market and potentially drive competition.
Bharat Biotech: Partnered with the International Vaccine Institute to develop their chikungunya vaccine candidate, BBV87. This vaccine is currently in Phase 3 clinical trials and could be another contender for market entry.
Defender Pharmaceuticals: Collaborated with the US Army Medical Research Institute of Infectious Diseases to develop their chikungunya vaccine candidate, TSIGSD-218. This vaccine is in Phase 2 clinical trials and may contribute to further research and development.
List of Chikungunya Vaccine Key companies in the market:
-
Allergan Inc (Ireland)
-
Merz Pharma (Germany)
-
Ipsen (France)
-
Valeant Pharmaceuticals (Canada)
-
Galderma (Switzerland)
-
Integra Lifesciences (Us)
-
Tei Biosciences
-
Fibrogen (Finland)